Contact this trialFirst, we need to learn more about you.
Panitumumab-IRDye800 for Brain Cancer
Recruiting2 awardsPhase 1 & 2
Palo Alto, California
This trial studies how well Panitumumab-IRDye800 works in making cancer cells glow during surgery for patients with malignant glioma. The glowing effect helps surgeons see and remove the tumor more accurately. Panitumumab-IRDye800 has been evaluated for its potential as a targeting agent for fluorescence detection of glioblastoma multiforme and high-grade gliomas.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service